ArticleClinical and experimental pediatrics2025
Dual-strain probiotics Bifidobacterium bifidum and Lactobacillus acidophilus reverse gut dysbiosis in preterm neonates: a randomized controlled trial.
Article in Clinical and experimental pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreterm neonates exhibit gut dysbiosis, characterized by increased numbers of pathogenic bacteria and decreased Bifidobacterium and Lactobacillus levels. Supplementation with the probiotic Bifidobacterium bifidum/Lactobacillus acidophilus (BB/LA) may reverse gut dysbiosis. PURPOSE: To study the effects of BB/LA on the gut microbiota of preterm neonates.
methodsWe enrolled neonates born between July 2022 and September 2023 with a gestational age of <33 weeks or birth weight of <1,500 g. After randomization into probiotic (PG) and control (CG) groups, stool samples were collected at 3 time points: birth (V1), 35 weeks' postmenstrual age (PMA) (V2), and 4 months of age (V3). BB/LA was administered to the PG until PMA 35 weeks. All neonates received a feeding protocol similar to that of predominant breast milk. Stool samples were stored at -80°C, a DNA extraction performed, and 16S rRNA gene sequencing used to define alpha and beta diversities and the relative abundances of the bacteria. Baseline characteristics and clinical outcomes were collected.
resultsWe analyzed 68 neonates (33 in the PG, 35 in the CG). The alpha diversities did not differ significantly between the groups at any time point. At V1, beta diversity was not significantly different between the 2 groups. After BB/LA supplementation (V2), beta diversity was significantly greater in the PG versus CG (P=0.004). The relative abundances of Bifidobacterium and Lactobacillus were higher in the PG (both P<0.001), whereas that of Clostridium senso stricto 1 was higher in the CG (P=0.017). Growth parameters, necrotizing enterocolitis, and mortality rate did not differ between groups. No adverse events were observed.
conclusionBB/LA led to healthier gut microbiota in preterm neonates as demonstrated by a reversal of gut dysbiosis characterized by increased beta diversity, increased the relative abundances of Bifidobacterium and Lactobacillus, and decreased the relative abundance of Clostridium senso stricto 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.